Screener
Cytokinetics CYTK Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $255,271 | $122,518 |
| Short-term investments | 910,415 | 759,703 |
| Accounts receivable, net | 24,432 | 17,764 |
| Inventories | 380 | — |
| Prepaid expenses and other current assets | 17,989 | 16,990 |
| Total current assets | 1,208,487 | 916,975 |
| Long-term investments | 538,317 | 335,048 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's accounts receivable?
- Cytokinetics (CYTK) reported accounts receivable of $24.43M in Q2 2026.
- How has Cytokinetics's accounts receivable changed year-over-year?
- Cytokinetics's accounts receivable increased by 190.5% year-over-year, from $8.41M to $24.43M.
- What is the long-term trend for Cytokinetics's accounts receivable?
- Over 5 years (2020 to 2025), Cytokinetics's accounts receivable has grown at a 32.1% compound annual growth rate (CAGR), from $4.42M to $17.76M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Cytokinetics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude